Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
NCT00171769
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
Persistent Nonvalvular Atrial Fibrillation
Interventions
DRUG:
Certoparin
Sponsor
Novartis